Vivoryon Therapeutics N.V. (LON:0R3M)

Vivoryon Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-3.62	-	10.76	-
Cost of Revenue	-	-0.53	-	1.57	-
Gross Profit	-	-3.1	-	9.2	-
Selling, General & Admin	6.9	8	8.91	4.55	2.81
Research & Development	14.06	17.64	20.22	17.45	13.21
Other Operating Expenses	0	-0.5	-0.02	-0.01	-0.01
Operating Expenses	20.96	25.14	29.11	21.99	16.01
Operating Income	-20.96	-28.24	-29.11	-12.8	-16.01
Interest Expense	-0.09	-0.06	-0.02	-0.02	-
Interest & Investment Income	0.48	0.48	0.04	0.02	0.03
Currency Exchange Gain (Loss)	-	-0.2	0.69	0.75	-0.48
Other Non Operating Income (Expenses)	-	0.04	0.05	-0.1	-0.02
EBT Excluding Unusual Items	-20.57	-27.98	-28.35	-12.15	-16.48
Merger & Restructuring Charges	-	-0.6	-	-	-
Gain (Loss) on Sale of Investments	-	-	-0.01	-0.08	-0.03
Pretax Income	-20.57	-28.58	-28.36	-12.22	-16.51
Income Tax Expense	-	-0.23	-0.2	0.43	-
Net Income	-20.57	-28.34	-28.16	-12.66	-16.51
Net Income to Common	-20.57	-28.34	-28.16	-12.66	-16.51
Shares Outstanding (Basic)	26	25	22	20	20
Shares Outstanding (Diluted)	26	25	22	20	20
Shares Change (YoY)	3.14%	14.64%	10.10%	0.12%	59.17%
EPS (Basic)	-0.79	-1.12	-1.28	-0.63	-0.83
EPS (Diluted)	-0.79	-1.12	-1.28	-0.63	-0.83
Free Cash Flow	-19.18	-21.56	-21.81	-11.28	-14.08
Free Cash Flow Per Share	-0.74	-0.85	-0.99	-0.56	-0.70
Gross Margin	-	-	-	85.42%	-
Operating Margin	-	-	-	-118.91%	-
Profit Margin	-	-	-	-117.57%	-
Free Cash Flow Margin	-	-	-	-104.77%	-
EBITDA	-20.82	-28.16	-29.04	-12.73	-15.96
EBITDA Margin	-	-	-	-118.22%	-
D&A For EBITDA	0.15	0.08	0.07	0.07	0.05
EBIT	-20.96	-28.24	-29.11	-12.8	-16.01
EBIT Margin	-	-	-	-118.91%	-

Updated Sep 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.